Abstract Objective To investigate the clinical significance of transforming growth factor-beta 1 (TGF-β1) in children with primary IgA nephropathy (IgAN). Methods Thirty children who were diagnosed with primary IgAN by renal biopsy between May 2008 and October 2012 were included in the study. Thirty healthy children were used as the control group. Urinary and blood TGF-β1 levels were measured using enzyme-linked immunosorbent assay, and the protein expression of TGF-β1 in the renal tissue was measured by immunohistochemistry. The correlation between TGF-β1 levels in blood, urine, and renal tissue and their relationship with clinical indices were analyzed. Results Children with primary IgAN had significantly higher urinary and blood TGF-β1 levels than the control group (Pr=0.557, P=0.001), and a significant positive correlation was also found between the TGF-β1 expression in the renal tissue and the pathological grade of renal tissue (r=0.682, Pr=0.038, P=0.844). Conclusions Urinary TGF-β1 level is significantly positively correlated with the pathological severity of disease in children with primary IgAN. Clinical measurement of urinary TGF-β1 may be of great practical value in predicting the progression and prognosis of chronic nephropathy.
Shen P, He L, Li Y, et al. Natural history and prognostic factors of IgA nephron pathy presented with isolated microscopic hematuria in Chinese patients [J]. Nephron Clin Pract, 2007, 106(4): c157-c161.
[2]
Yata N, Nakanishi K, Shima Y, et al. Improved renal survival in Japanese children with IgAN[J]. Pediatr Nephrol, 2008, 23(6): 905-912.
[3]
Pohl M. Risikofaktoren für den Verlauf der IgA-Nephropathie[J]. Der Nephrologe, 2011, 6(4): 340-341.
[4]
Strutz F, Okada H, Neilson EG. The role of the tubular epithelial cell in renal fibrogenesis[J]. Clin Exp Nephrol, 2001, 5(2): 62-74.
[5]
Cattran DC, Coppo R, Cook HT, et al. The Oxford classification ofIgAN: rationale, clinicopathological correlations, and classification[J]. Kidney Int, 2009, 76(5): 534-545.
Kalliakmani P, Nakopoulou L, Tsakas S, et al. Urinary interleukin-6 (IL-6) and transforming growth factor (TGF-β) levels in corticosteroidtreated patients withIgAN[J]. Clin Nephrol, 2011, 76(2): 144-150.
[9]
Goumenos DS, Tsakas S, El Nahas AM, et al. Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria[J]. Nephrol Dial Transplant, 2002, 17(12): 2145-2152.
[10]
Shin GT, Kim SJ, Ma KA, et al. ACE inhibitors attenuate expression of rena l transforming growth factor-beta1 in humans[J]. Am J Kidney Dis, 2000, 36(5): 894-902.
[11]
D'Amico G. Natural history of idiopathicIgAN and factors predictive of disease outcome[J]. Sem Nephrol, 2004, 24(3): 179-196.
[12]
Wang H, Fu W, Jin Z, et al. Advanced IgAN with impaired renal function benefits from losartan treatment in rats[J]. Ren Fail, 2013, 35(6): 812-818.
[13]
Song JH, Lee SW, Suh JH, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy[J]. Clin Nephrol, 2003, 60(5): 318-326.
